-
Generics: how to innovate in imitation?
Time of Update: 2017-04-18
With the increasing proportion of generic drugs in the drug market, its dominant advantage in emerging markets is more and more obvious China is a big country of generic drugs, and more than 95% of th
-
These products will explode in 2017, with a total revenue of over 100 billion!
Time of Update: 2017-04-16
According to the forecast of cortellis competitive intelligence database, 9 of the new drugs to be launched in 2017 will reach the blockbuster level (with annual sales of more than US $1 billion) or c
-
Analysis of Pfizer's best selling drugs in 2016
Time of Update: 2017-04-16
When it comes to Pfizer, we are all familiar Pfizer is the No 1 pharmaceutical company in the world, starting with santaonian, terramycin and penicillin, and now has nearly 100000 employees in 150 cou
-
In 2017, Forbes listed 30 potential Chinese medical and health enterprises
Time of Update: 2017-04-13
Forbes China recently released the "2017 China potential enterprise list", presenting three lists for the first time, including the list of potential enterprises of listed companies, the list of poten
-
Prediction of new varieties: 25 high quality varieties that are expected to reconstruct the market
Time of Update: 2017-04-13
Before that, after the adjustment of the 2009 version of the medical insurance catalog, a number of large-scale varieties were born, such as entecavir, rat nerve growth factor, rosuvastatin, edaravone
-
President of Bayer prescription drugs in China: 13 billion sales in China in 2016
Time of Update: 2017-04-13
On April 11, Bayer Group announced its performance in China in 2016: 1.8 billion euros (more than 13 billion yuan in total) For many years in a row, Bayer Group's prescription drug business has been d
-
2017q1: inventory of class 1 new drugs approved by CDE
Time of Update: 2017-04-12
Hl-085 and its capsule were developed by Shanghai Kezhou pharmaceutical R & D Co., Ltd and Tianjin Binjiang pharmaceutical R & D Co., Ltd It is speculated that this product is a mitogen activated extr
-
How can local generic companies break through the unique patent of hepatitis C in China?
Time of Update: 2017-04-12
We must be familiar with sofibuvir, the "God drug of hepatitis C", which has just submitted its application for listing in China Such a hot drug, of course, can not avoid a battle around patent attack
-
Who has invested the most in R&D among the 14 listed pharmaceutical companies with revenues exceeding RMB 10 billion?
Time of Update: 2017-04-12
Wonderful content passed quietly in the first quarter of 2017, and the disclosure of 2016 annual report of listed pharmaceutical companies was coming to an end, and the report card of a number of phar
-
PK of 10 billion pharmaceutical companies: step, Hengrui, Shangyao, China biology
Time of Update: 2017-04-10
With more and more listed companies unveiling the mystery of annual report, most of the major pharmaceutical companies listed in A-share and H-share in China have published their transcripts Although
-
12 pharmaceutical companies ranked among the "1 billion club"
Time of Update: 2017-04-09
As of April 6, 12 of the listed pharmaceutical companies that have published their 2016 annual reports have made net profits in the "1 billion club" Among them, Shanghai Pharmaceutical ranked first wi
-
Eight "blockbusters" are on the market this year!
Time of Update: 2017-04-08
According to the report of "2017's most noteworthy drugs" released by corewellian, 8 of the drugs on the market in 2017 will reach the blockbuster level of sales in 2021 Six of the drugs have submitte
-
Who is the famous brand of pharmaceutical enterprises released by Tsinghua University?
Time of Update: 2017-04-06
Listed companies represent the vanguard and vitality of China's economy, and brand is the comprehensive embodiment of enterprise competitiveness In the economic development and market competition, enterprises should understand the development situation and trend of the industry, dynamically track the investment performance of brands, and improve the efficiency of brand management.
-
Against the sky, the net profit increased nearly 60 times! Guangyuyuan's "report card" is bright and blind
Time of Update: 2017-04-05
Recently, guangyuyuan published its 2016 report card, realizing a revenue of 937 million yuan, a year-on-year increase of 118.70%, and a net profit of 123 million yuan attributable to shareholders of
-
Reminisce of the past tycoons: they have worked hard to change the pharmaceutical industry!
Time of Update: 2017-04-04
On the clear and bright rain, the chrysanthemum is folded to send Acacia, playing the piano and singing Always in the Qingming season, consciously or unconsciously think of many people, sometimes a na
-
Salary list of big boss of pharmaceutical enterprises: some people increased by 318%, others reduced by 1.5 million
Time of Update: 2017-03-31
What's the "salary" of the drug tycoons in 2016? E-medicine managers exclusively sorted out the remuneration of the leaders of 61 listed pharmaceutical companies, some of them still ranked first, some
-
How to dig the "virgin land" market with the help of priority approval of "fast lane" 7 varieties?
Time of Update: 2017-03-31
The priority review and approval procedure for excellent contents has opened a "convenient door" for the rapid marketing of drugs According to the 2016 drug review report, a total of 7 varieties (excl
-
Two executives of Fosun Group resigned on one day. The company's 2017 target is 16.6 billion revenue!
Time of Update: 2017-03-30
Liang Xinjun, one of the "four swordsmen" of Fosun Group, resigned naked, while song Jinsong, senior vice president of Fosun Pharmaceutical, also resigned on the same day, but what about the resignati
-
There's BeDa's trouble! Great changes have taken place in the drug market of NSCLC!
Time of Update: 2017-03-26
On March 24, asitini of AstraZeneca was approved for listing; on March 17, Bi announced that afatini officially landed in China; in February, Qilu pharmaceutical gefitini's first generic product was a
-
Verofinil, a new Roche melanoma drug, was approved in China
Time of Update: 2017-03-24
As the leader of this research in China, I feel honored and gratified that our country's BRAF mutant melanoma patients finally have effective treatment drugs!
